Pomerantz Law Firm Launches Investigation into EyePoint, Inc. for Shareholder Claims
Pomerantz LLP, a leader in corporate and securities class-action litigation, is taking steps to investigate claims for investors of EyePoint, Inc. (NASDAQ: EYPT). This investigation has arisen following steep declines in the company's stock price prompted by disappointing results from two pivotal Phase 3 clinical trials. Investors who have suffered losses are encouraged to connect with Danielle Peyton at Pomerantz for further assistance.
EyePoint's troubles began on August 17, 2026, when the company released findings from its LUGANO trial, evaluating the efficacy of DURAVYU™ (vorolanib intravitreal insert) in treating wet age-related macular degeneration (wet AMD). The results indicated that the treatment did not meet its primary endpoint compared to the existing standard, Eylea, leading to a cascade of negative repercussions for the company. In response to this announcement, EyePoint experienced a drastic drop in stock value, with shares plummeting nearly 67%, closing at $4.87.
The situation worsened on October 19, 2026, when EyePoint disclosed unsatisfactory topline results from its subsequent trial, LUCIA, which evaluated Duravyu’s effectiveness in a similar capacity. Not only did the results fail to meet the expected non-inferiority criteria compared to Eylea, but the announcement also included drastic cost-cutting measures. The company decided to terminate its late-stage clinical program and conduct a significant workforce reduction of 53%. These decisions led to a catastrophic fall of 85.28% in stock value, closing at merely $0.44.
This sequence of events raises critical questions about EyePoint's governance and whether any of its executives or board members might have engaged in securities fraud or other unlawful business practices. As Pomerantz investigates these concerns, they emphasize the importance of protecting investor interests, particularly for those feeling the financial impact of the aforementioned events.
Founded by Abraham L. Pomerantz, who is considered a pioneer in securities class actions, Pomerantz LLP has a history spanning over 85 years of advocating for investor rights and pursuing justice against corporate misconduct. The firm has previously secured numerous multimillion-dollar settlements for its clients, reinforcing its position as a trusted ally for individuals affected by securities fraud.
For shareholders of EyePoint Inc. who feel aggrieved, now is an opportune moment to explore possible legal recourse. They can reach out to Pomerantz's dedicated team to find out more about joining a potential class action lawsuit or learning about their individual options for recovery. As Pomerantz continues its investigation into EyePoint, the implications for the company and its investors remain to be seen.
As the landscape for EyePoint unfolds, it illustrates larger themes within the biotech industry, where clinical trials can dramatically shift investor fortunes overnight. This situation serves as a reminder for investors to remain vigilant and informed, particularly in the high-stakes world of pharmaceuticals where the results of one trial can dictate the future of a company.
To connect with Pomerantz LLP regarding this investigation or to learn how to join the securities fraud claims, contact Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980.
EyePoint's troubles began on August 17, 2026, when the company released findings from its LUGANO trial, evaluating the efficacy of DURAVYU™ (vorolanib intravitreal insert) in treating wet age-related macular degeneration (wet AMD). The results indicated that the treatment did not meet its primary endpoint compared to the existing standard, Eylea, leading to a cascade of negative repercussions for the company. In response to this announcement, EyePoint experienced a drastic drop in stock value, with shares plummeting nearly 67%, closing at $4.87.
The situation worsened on October 19, 2026, when EyePoint disclosed unsatisfactory topline results from its subsequent trial, LUCIA, which evaluated Duravyu’s effectiveness in a similar capacity. Not only did the results fail to meet the expected non-inferiority criteria compared to Eylea, but the announcement also included drastic cost-cutting measures. The company decided to terminate its late-stage clinical program and conduct a significant workforce reduction of 53%. These decisions led to a catastrophic fall of 85.28% in stock value, closing at merely $0.44.
This sequence of events raises critical questions about EyePoint's governance and whether any of its executives or board members might have engaged in securities fraud or other unlawful business practices. As Pomerantz investigates these concerns, they emphasize the importance of protecting investor interests, particularly for those feeling the financial impact of the aforementioned events.
Founded by Abraham L. Pomerantz, who is considered a pioneer in securities class actions, Pomerantz LLP has a history spanning over 85 years of advocating for investor rights and pursuing justice against corporate misconduct. The firm has previously secured numerous multimillion-dollar settlements for its clients, reinforcing its position as a trusted ally for individuals affected by securities fraud.
For shareholders of EyePoint Inc. who feel aggrieved, now is an opportune moment to explore possible legal recourse. They can reach out to Pomerantz's dedicated team to find out more about joining a potential class action lawsuit or learning about their individual options for recovery. As Pomerantz continues its investigation into EyePoint, the implications for the company and its investors remain to be seen.
As the landscape for EyePoint unfolds, it illustrates larger themes within the biotech industry, where clinical trials can dramatically shift investor fortunes overnight. This situation serves as a reminder for investors to remain vigilant and informed, particularly in the high-stakes world of pharmaceuticals where the results of one trial can dictate the future of a company.
To connect with Pomerantz LLP regarding this investigation or to learn how to join the securities fraud claims, contact Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.